I hope you’re right! That being said you can still mention the cheap cost of manufacturing to signal the potential for high margins.
We should look at the price of ezetimibe (Zetia) at launch. I would expect a similar price for obicetrapib as they’re both cheap 10-mg pills created to be used on top of statins for people at high risk. However depending on the source I find that Zetia was launched at $70/month or $500/month Is there a way to find the “official” launch price?
Results from observational studies, Mendelian randomization analyses, and randomized clinical trials support the potential of CETP inhibition to reduce atherosclerotic cardiovascular disease (ASCVD) risk through a reduction of apolipoprotein B-containing lipoproteins.
It basically seems that it will prevent all diseases, wonder drug, but we’ll probably have to wait and see longer for the other indications.
At present, there is robust evidence to support the potential benefits of reducing CETP for ASCVD risk reduction and increasing indications of its ability to promote longevity by reducing risks of several other conditions including T2D, dementia, CKD, AMD, and septicemia. Ongoing clinical trials of obicetrapib are expected to provide further insight into CETP inhibition as a therapeutic target.
Yes, it looks like a wonder drug. I’m discussing with John Kastelein and the NewAmsterdam Pharma team to get some obicetrapib shipped to Ora Biomedical to see if it extends the lifespan in C. Elegans. They’re interested. Wait and see…
Why wouldn’t they request the ITP to study their compound as well (unless they haven’t already)? Perhaps they don’t see the value in them doing it, and someone else have to write up the request.
On the pricing thing, Kastelein clearly states his intent to keep the price down, and NAM has an unusual corporate structure that may let them resist the market pressure to maximize revenue; we’ll just have to see. It would be great if it were modestly-priced right out of the gate.
As Antoine suggests, they may well not know about ITP: Kastelein is a cardiologist who takes care of kids with FH, not a biogerontologist. In his recent article on CETP inhibition (=obicetrapib) for "reducing risk of morbidity and promoting longevity", previously posted by Antoine, they don’t mention the ITP, rapa, the Hallmarks of Aging,geroscience, biogerontology, or anything else that would make you think they’re aware that you can actually target aging.
If I were running things over at [NewAmsterdam Pharma], I would price them so low that I would obliterate, If the drugs turn out as good as we think they are… they are not just going to eradicate apoB, they’re going to dramatically reduce your risk of Alzheimer’s disease, and reduce your risk of diabetes profoundly. That’s three of the four horsemen you just whacked, with one drug.
I’m not complaining about the chemistry, it could be amazing but what the heck is going on with the name? Do any of the letters mean something to anybody or is it just 11 random letters from a scrabble bag that dumped on the floor?
Heterozygous CETP protein-truncating variant carrier status reduced atherosclerotic disease risk (odds ratio, 0.70; 95% confidence interval, 0.57– 0.85; P=5×10-4). In clinical trials, we observed a significant interaction between the magnitude and duration of LDL lowering on treatment effects (hazard ratio, 0.69 per 10– mmol/L×years; 95% confidence interval, 0.52–0.90; P=0.007), supporting that reducing cumulative LDL exposure is key to lowering cardiovascular risk. When comparing genetics with trial outcomes, accounting for differences in timing, duration, and follow-up, we observed consistent effects on atherosclerosis-related events per LDL years across genetic and pharmacological CETP inhibition, as well as with statins, ezetimibe, PCSK9 inhibitors, and familial hypercholesterolemia-associated variants (hazard ratio, 0.74 and 0.69 per 10–mmol/L×years, respectively). This suggests that CETP inhibition reduces cardiovascular risk primarily through LDL. Notably, several trials failed to achieve sufficient cumulative LDL reduction to impact clinical events, and this was not unique to CETP inhibitors.
Our findings indicate that future CETP inhibitor trials achieving substantial and sustained LDL reduction will demonstrate efficacy in preventing cardiovascular events. These results highlight the importance of long-term LDL lowering and support further investigation of CETP inhibition as a strategy for cardiovascular prevention.
Is there a way to find the “official” launch price?
Preprint by the NewAmsterdam Pharma team